赛升药业启动公司章程修订 同步完善公司治理制度 强化规范运作

Core Viewpoint - Beijing Saiseng Pharmaceutical Co., Ltd. announced the approval of amendments to its Articles of Association and related governance systems to enhance compliance and governance structure, ensuring alignment with regulatory requirements [1][2][3] Group 1: Articles of Association Revision - The revision of the Articles of Association is based on various laws and regulations, including the Company Law and Securities Law of the People's Republic of China, aimed at optimizing systems and ensuring effective alignment with the latest regulatory frameworks [2] - The proposed amendments will be submitted for approval at the company's second extraordinary general meeting of shareholders in 2025, with management authorized to handle subsequent registration matters [2] Group 2: Governance System Improvement - In addition to revising the Articles of Association, the company is also updating its governance-related systems to enhance operational standards and governance structure [3] - The revisions and new systems are intended to strengthen internal governance and provide a solid foundation for sustainable development, responding to regulatory requirements and improving decision-making efficiency and risk management capabilities [3]